Bengaluru-based Peptris raised Rs 70 crore (USD 7.7M) Series A to advance AI-generated drugs to clin...
The AMW Read
Updates the player map for the AI drug discovery sub-segment within Vertical AI (Healthcare/Bio) with a notable Series A raise in the Indian ecosystem.
NoveltySignificance
Healthcare & Bio ยท Player Map
Bengaluru-based Peptris raised Rs 70 crore (USD 7.7M) Series A to advance AI-generated drugs to clinical stage within 24 months, targeting oncology, rare diseases, and women's health. This signals India's emergence as an innovation hub in AI drug discovery, moving beyond molecule generation to clinical-ready assets. With 173+ AI drug programs globally and pivotal Phase III trials in 2026, Peptris' approach of novel molecules plus drug repurposing addresses the $2.6B cost and decade-long timeline of traditional pharmaceutical R&D.
#AIDrugDiscovery #HealthTech #Pharmaceuticals #Biotech #Innovation #Startups #Healthcare
